Beta Drugs Limited presents FY26 annual results with financial performance and balance sheet data showing growth in reserves and assets.
Company outlines strategic transformation roadmap 'Beta Vision 2030' focusing on exports, API integration, and entry into IVF segment through Nivian.
Oncology portfolio includes 135+ products with 19 new products under development and successful launches of Olaparib and Acalabrutinib.
API business expansion includes Rs 20+ Cr investment in backward integration and exports to non-regulated markets.